CAT's Second Pivotal Trabio Trial Fails to Meet Primary Endpoint

Cambridge Antibody Technology (CAT) has announced that in its second pivotal (International Phase III) clinical trial of Trabio failed to meet the primary endpoint of improving the outcome of surgery for glaucoma.

This result is consistent with the result of the first pivotal (European Phase II/III) clinical trial, which was announced in November 2004. CAT is now terminating further development of Trabio as a potential treatment for improving the outcome of glaucoma surgery, as indicated in November 2004. Also in November 2004, CAT announced that it would be minimizing, from that time, all future costs in connection with Trabio development.